Lucy Scientific Discovery, Inc.: M&A transaction — Lucy Scientific completes acquisition of Wesana's SANA-013 assets; forms Lucy Discoveries Holdings

Lucy Scientific Discovery, Inc.

Acquired SANA-013, a psilocybin/CBD combination therapy for MDD, migraine, cluster headaches, and trigeminal neuralgia.
Consideration: $300K cash, $177,974 in installments through April 2024, 1M common shares, and assumption of $92K debt.
Formed Lucy Discoveries Holdings to advance psychedelic medicine R&D and diversify its therapy pipeline.
Wesana CEO Daniel Carcillo will join Lucy; transaction closed June 30, 2023, press release dated July 5.

item 1.01 item 2.01 item 3.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

M&A Transactions SEC 8-K Item 2.01/5.01 confidence 0.9

Lucy Scientific Discovery, Inc. completed an acquisition involving Wesana Health Holdings Inc. (closed 2023-06-30).

Action: acquisition
Counterparty: Wesana Health Holdings Inc.
Closing: 2023-06-30

Exact text from the filing

On June 30, 2023, the Closing occurred. A total of $100,000 was paid by the Company to Wesana on July 5, 2023 and the Shares were issued on June 30, 2023.

View on SEC.gov

Browse all m&a transactions →

Source: SEC EDGAR

accession 0001213900-23-055368

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.